Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

SMART China, A Multi-center Clinical Registry Study

Condition:   Atrial Fibrillation
Intervention:   Device: THERMOCOOL® SMARTTOUCH® (RF ablation treatment)
Sponsor:   Biosense Webster, Inc.
Not yet recruiting - verified June 2015

PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   University of Pittsburgh;   UPMC;   Johns Hopkins University;   Penn State University;   Temple University
Recruiting - verified June 2015

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany and the UK: REACT-AF2

Condition:   Non-valvular Atrial Fibrillation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   IMS Health;   Oxon Epidemiology
Active, not recruiting - verified June 2015

Adherence to New Oral Anticoagulation Therapy in Turkey

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Cardiovascular Academy Society, Turkey
Recruiting - verified July 2015

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

Conditions:   Pain;   Chronic Pain;   Mental Disorders;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2;   Arthritis
Interventions:   Other: Unblinded to Genetic Testing Results;   Other: Blinded to Genetic Testing Results
Sponsor:   Proove Bioscience, Inc.
Recruiting - verified June 2015

Comparison Between Thoracoscopic Left Atrial Appendage Excision and Warfarin for the Secondary Prevention of Stroke in Patients With AF

Conditions:   Atrial Fibrillation;   Stroke;   Systemic Embolism
Interventions:   Procedure: Thoracoscopic Left Atrial Appendage Excision;   Drug: Warfarin
Sponsor:   The First Hospital of Nanjing Medical University
Active, not recruiting - verified June 2015

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ACP-196;   Drug: ibrutinib
Sponsor:   Acerta Pharma BV
Recruiting - verified June 2015

Real-Life Evidence on Stroke Prevention in SPAF

Condition:   Atrial Fibrillation (Prevention of Stroke)
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists
Sponsors:   Bayer;   Janssen, LP
Recruiting - verified June 2015

Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach

Conditions:   Atrial Fibrillation;   Persistent or Longstanding Persistent Atrial Fibrillation
Intervention:   Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation
Sponsor:   AtriCure, Inc.
Recruiting - verified June 2015

Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects

Condition:   Sleep Disorders
Intervention:  
Sponsor:   Itamar-Medical, Israel
Recruiting - verified June 2015

Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.

Condition:   Vasoplegic Syndrome
Interventions:   Drug: Norepinephrine;   Drug: Norepinephrine
Sponsor:   Centre Hospitalier Universitaire, Amiens
Recruiting - verified June 2015

Prospective, Randomized Comparison of Hybrid Ablation vs. Catheter Ablation (PRHACA)

Condition:   Persistent Atrial Fibrillation
Interventions:   Device: endocardial ablation (Medtronic);   Device: hybrid surgical ablation (nContact)
Sponsor:   Jasbir Sra
Recruiting - verified June 2015

Canadian Community Utilization of Stroke Prevention Study - Emergency Department

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Other: Retrospective review of OAC prescription;   Other: Prescription of OAC in ED;   Other: Community AF clinic
Sponsor:   Population Health Research Institute
Recruiting - verified June 2015

Multipolar Mapping and Atrial Arrhythmias

Condition:   Atrial Fibrillation or Atrial Flutter
Intervention:   Device: Constellation Full Contact Mapping Catheter
Sponsor:   Angelo Biviano
Recruiting - verified June 2015

Evaluation of 5 Days Holter and 30 Days Thumb-ECG for Detection of Atrial Fibrillation in Stroke Patients

Conditions:   Atrial Fibrillation;   Stroke
Intervention:   Device: Holter monitoring and Thumb ECG
Sponsor:   Herlev Hospital
Completed - verified June 2015

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Phenprocoumon
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2015

Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Right Ventricle (RV) Markers of Future Pacing Induced Ventricular Dysfunction - Pilot

Condition:   Sick Sinus Syndrome
Intervention:  
Sponsors:   Basildon and Thurrock University Hospitals NHS Foundation Trust;   Anglia Ruskin University
Recruiting - verified June 2015

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Condition:   Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Sotalol;   Drug: Placebo for BMS-919373
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2015

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified April 2015

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Condition:   Postoperative Atrial Fibrillation
Interventions:   Drug: Amiodarone;   Procedure: DC-cardioversion;   Drug: Rate Control
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Neurological Disorders and Stroke (NINDS);   Canadian Institutes of Health Research  (CIHR)
Active, not recruiting - verified June 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified June 2015

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

The Role of Nerves in the Heart That Trigger Pulmonary Vein Extra Beats

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Procedure: Pulmonary vein isolation;   Procedure: Ganglionic plexi ablation
Sponsor:   Imperial College London
Recruiting - verified June 2015

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Condition:   Current or Recent History of Atrial Fibrillation
Interventions:   Drug: bucindolol hydrochloride;   Drug: metoprolol succinate
Sponsors:   ARCA Biopharma, Inc.;   Medtronic
Recruiting - verified July 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

A Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Device: VytronUS Ablation System
Sponsor:   VytronUS, Inc.
Completed - verified June 2015

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Condition:   Non-valvular Atrial Fibrillation
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified December 2014

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified June 2015

Anticoagulant Utilization Pattern

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified June 2015

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified June 2015

Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems

Conditions:   Atrial Fibrillation;   Tachycardia;   ICD Therapy;   Thromboembolic Events;   Heart Failure
Intervention:  
Sponsor:   Biotronik SE & Co. KG
Recruiting - verified June 2015

DF4 Master Study (Safety and Efficacy Study)

Conditions:   Ventricular Tachycardia;   Ventricular Fibrillation;   Sudden Cardiac Death;   Heart Failure
Intervention:   Device: Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego
Sponsor:   Biotronik SE & Co. KG
Active, not recruiting - verified June 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Prazaxa
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified July 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis

Condition:   Moderate Mitral Stenosis
Intervention:   Procedure: Percutaneous Mitral Commissurotomy
Sponsor:   Asan Medical Center
Recruiting - verified June 2015

Get CardioSmart

You're Invited

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points